Generic: L-Norgest/E.Estradiol-E.Estrad | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $6.2K | 50 | 40 | $1.36 |
| 2020 | $40.9K | 318 | 224 | $1.41 |
| 2021 | $160.1K | 1,768 | 752 | $0.9934 |
| 2022 | $136.5K | 1,615 | 733 | $0.9265 |
| 2023 | $198.2K | 2,687 | 1,135 | $0.8099 |
| State | Total Drug Cost | Claims | Prescribers | Beneficiaries |
|---|---|---|---|---|
| New York | $17.7K | 162 | 77 | 67 |
| North Carolina | $13.4K | 179 | 84 | 82 |
| Texas | $10.4K | 127 | 58 | 55 |
| Florida | $9.3K | 153 | 74 | 67 |
| Illinois | $8.4K | 117 | 45 | 42 |
| Massachusetts | $7.9K | 148 | 64 | 58 |
| Michigan | $7.6K | 78 | 40 | 35 |
| Tennessee | $7.0K | 114 | 57 | 55 |
| Wisconsin | $6.9K | 103 | 43 | 38 |
| Ohio | $6.6K | 73 | 38 | 36 |
| Virginia | $6.5K | 87 | 45 | 40 |
| Alabama | $6.4K | 56 | 25 | 24 |
| Indiana | $6.3K | 78 | 29 | 29 |
| South Carolina | $6.2K | 82 | 40 | 38 |
| California | $6.0K | 94 | 43 | 41 |
| Kentucky | $5.4K | 77 | 38 | 34 |
| Missouri | $5.3K | 70 | 32 | 28 |
| Pennsylvania | $4.9K | 76 | 40 | 38 |
| Maine | $4.8K | 53 | 31 | 30 |
| Connecticut | $4.6K | 87 | 36 | 36 |
| Georgia | $3.8K | 55 | 25 | 25 |
| Maryland | $3.8K | 44 | 22 | 20 |
| Iowa | $3.7K | 54 | 25 | 22 |
| Louisiana | $3.6K | 54 | 26 | 21 |
| Minnesota | $2.5K | 30 | 11 | 11 |
| New Mexico | $2.4K | 44 | 19 | 16 |
| Oklahoma | $2.2K | 30 | 14 | 11 |
| Nebraska | $2.1K | 21 | 8 | N/A |
| Washington | $2.0K | 35 | 16 | 15 |
| Arizona | $1.9K | 38 | 14 | 14 |
| New Jersey | $1.9K | 44 | 19 | 18 |
| Oregon | $1.7K | 26 | 13 | 13 |
| Colorado | $1.7K | 27 | 13 | 11 |
| Mississippi | $1.6K | 11 | 7 | N/A |
| West Virginia | $1.4K | 21 | 7 | N/A |
| Arkansas | $1.2K | 12 | 6 | N/A |
| Nevada | $1.0K | 23 | 8 | N/A |
| Idaho | $990.74 | 14 | 8 | N/A |
| Vermont | $768.02 | 12 | 8 | N/A |
| Rhode Island | $737.86 | 18 | 8 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.
Explore More Data Tools
For adjacent public-data tools, methodology notes, and network updates, visit DataPeek Facts.